Related Experiment Video

Updated: Aug 16, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

GSTM1 polymorphism in patients with clinical manifestations of atherosclerosis

D A Rodrigues1,2,3, J V M Martins1,2,3, K S F E Silva4,5

  • 1Pontifícia Universidade Católica de Goiás, Goiânia, GO, Brasil.

Genetics and Molecular Research : GMR
|April 1, 2017
PubMed

Insights

The GSTM1 present genotype is linked to a higher risk of atherosclerosis, particularly in individuals who smoke. This genetic factor may influence the development of this common cardiovascular disease.

Area of Science:

  • Cardiovascular Science
  • Genetics
  • Epidemiology

Background:

  • Atherosclerosis, characterized by arterial plaque buildup, is a leading cause of cardiovascular disease.
  • Numerous modifiable and non-modifiable risk factors contribute to atherosclerosis development.
  • Genetic polymorphisms, such as those in Glutathione S-transferase (GST) genes, are investigated for their role in disease onset.

Purpose of the Study:

  • To investigate the association between Glutathione S-transferase mu 1 (GSTM1) gene polymorphisms and atherosclerosis.
  • To determine if GSTM1 genotype influences atherosclerosis risk in relation to smoking habits.

Main Methods:

  • Case-control study comparing individuals with atherosclerosis to a healthy control group.
  • Genotyping analysis to identify GSTM1 present and null genotypes.
  • Statistical analysis to assess genotype frequencies and correlations with risk factors like smoking.

Main Results:

  • The GSTM1 present genotype was observed 1.2 times more frequently in individuals with atherosclerosis compared to controls.
  • A significant association was found between the GSTM1 present genotype and smoking, with higher prevalence in smokers with atherosclerosis.
  • The GSTM1 present genotype was also more frequent in former smokers with atherosclerosis, particularly those with longer smoking histories.

Conclusions:

  • GSTM1 gene polymorphisms may play a role in the pathogenesis of atherosclerosis.
  • Smoking appears to be a significant interacting factor with the GSTM1 present genotype in increasing atherosclerosis risk.
  • Further research into genetic predispositions and environmental factors like smoking is crucial for understanding atherosclerosis.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...